CNS Pharmaceuticals Inc. (CNSP)
NASDAQ: CNSP
· Real-Time Price · USD
4.96
-1.07 (-17.74%)
At close: Aug 15, 2025, 3:59 PM
5.09
2.62%
After-hours: Aug 15, 2025, 04:10 PM EDT
-17.74% (1D)
| Bid | 4.95 |
| Market Cap | 2.63M |
| Revenue (ttm) | 3.14K |
| Net Income (ttm) | -15.61M |
| EPS (ttm) | -63.64 |
| PE Ratio (ttm) | -0.08 |
| Forward PE | -0.49 |
| Analyst | Buy |
| Ask | 5.35 |
| Volume | 68,553 |
| Avg. Volume (20D) | 27,365.9 |
| Open | 6.31 |
| Previous Close | 6.03 |
| Day's Range | 4.93 - 6.33 |
| 52-Week Range | 4.93 - 222.00 |
| Beta | 0.76 |
About CNSP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CNSP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CNSP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 hours ago
CNS Pharmaceuticals shares are trading lower. The ...
Unlock content with
Pro Subscription
4 weeks ago
-10.7%
CNS Pharmaceuticals shares are trading lower after the company announced a 1-for-12 reverse split.
1 month ago · accessnewswire.com
CNS Pharmaceuticals Participates in Virtual Investor CEO Connect SegmentHOUSTON, TX / ACCESS Newswire / July 9, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri...
3 months ago · accessnewswire.com
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdateCash expected to fund operations into the second half of 2026 Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multi...